Sino Biological的ARS-CoV-2變異體和中和抗體

Sino Biological的ARS-CoV-2變異體和中和抗體

2021.05.28

本文轉載至原廠電子報: Sino Biological  https://www.sinobiological.com/  原廠電子報

Online View

Variants and Neutralizing Antibodies for SARS-CoV-2

SARS-CoV-2 Spike Variants

Several new variants of SARS-CoV-2 virus have emerged in recent months. The U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351, and the most recent India variant B.1.617 are of particular concern because of their high prevalence. Sino Biological has newly launched RBD and Spike proteins of these variants.

Recombinant RBD Variants

Lineage

Mutations

Cat#

Tag

B.1.1.7

N501Y

40592-V02H1

Fc

B.1.1.7

N501Y

40592-V08H82

His

B.1.1.7

N501Y

40592-V31H1

rFc

B.1.351

K417N, E484K, N501Y

40592-V08H85

His

B.1.351

E484K

40592-V31H2

rFc

B.1.351

K417N, E484K, N501Y

40592-V31H4

rFc

B.1.351

K417N

40592-V31H6

rFc

B.1.617

L452R, E484Q

40592-V08H88

His

P.1

K417T, E484K, N501Y

40592-V08H86

His

P.1

K417T, E484K, N501Y

40592-V31H5

rFc

P.1

K417T

40592-V31H7

rFc

Recombinant S1+S2 ECD Variants

Lineage

Mutations

Cat#

Tag

B.1.1.7

HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H

40589-V08B6

His

B.1.351

L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, A701V

40589-V08B7

His

B.1.351

D80A, K417N, E484K, N501Y, D614G, A701V

40589-V08B9

His

P.1

L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F

40589-V08B10

His

P.1

L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

40589-V08B8

His

 

150+ SARS-CoV-2 Variants

 

SARS-CoV-2 Neutralizing Antibodies

Some of the above mutations may have allowed the virus to escape from neutralizing antibodies. To characterize these variants, a new panel of monoclonal antibodies has been launched. These antibodies demonstrate differential neutralizing activities against different variants validated by Competitive ELISA Assay. Notably, the B.1.351 and P.1 variants seem to be immune to a subset of the antibodies.

Neutralization Activity by Competitive ELISA Assay

Neutralizing
Antibodies

WT RBD

Recombinant RBD

Recombinant S1

B.1.1.7

B.1.351

P.1

B.1.617

B.1.617

B.1.429

40150-D001

++

+

++

++

++

++

++

40150-D002

++

+

+

++

++

++

++

40591-MM43

++

++

++

++

++

++

++

40592-MM57

+

+

+

+

+

40592-R001

+++

+++

+++

+++

+++

40592-R118

+++

+++

+

+

+

40592-R117

+++

+++

+++

+++

+++

+: Neutralizing Capacity

Neutralizing Antibodies for SARS-CoV-2

The Aforementioned Antigens

u27.png
40150-D001
u28.png
40592-MM57

Recombinant RBD:

WT: 40592-V08B

B.1.1.7 | U.K. Variant
40592-V08H82 (N501Y)

B.1.351 | South Africa Variant
40592-V08H85 (K417N, E484K, N501Y)

P.1 | Brazil Variant
40592-V08H86 (K417T, E484K, N501Y)

B.1.617 | India Variant
40592-V08H88 (L452R, E484Q)

 

Recombinant S1:

B.1.617 | India Variant
40591-V08H19 (E154K, E484Q, L452R, D614G, P681R)

B.1.429 | California Variant
40591-V08H17 (W152C, L452R, D614G)

 

 

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!